Literature DB >> 19508155

Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis.

Hwa-Jung Kim1, Jae-Ho Lee, Se-Hyuk Kim.   

Abstract

To investigate the therapeutic effects and mechanisms of action of human mesenchymal stem cells (hMSCs), rats were intravenously treated with hMSCs 24 h after traumatic brain injury (TBI). Neurological function was significantly recovered in the hMSC-treated group by 15 days after TBI compared to the placebo group treated with saline. Quantitative ELISA of extracts from the entire traumatized cerebral hemispheres showed significantly increased expression of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) in the hMSC group at 2 days after TBI, with expression decreasing over time. Western blot analysis demonstrated that pAkt expression was upregulated at 2 days after TBI, and caspase-3 cleavage was significantly decreased at 8 days after TBI in the hMSC group. Our results show that treatment of TBI with hMSCs during the acute phase of injury can enhance neurological functional outcome, and suggest that increased levels of neurotrophic factors in the injured hemisphere leading to decreased neuronal apoptosis is one mechanism by which functional recovery may occur.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19508155     DOI: 10.1089/neu.2008.0818

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  71 in total

Review 1.  Regenerative chemical biology: current challenges and future potential.

Authors:  Ada Ao; Jijun Hao; Charles C Hong
Journal:  Chem Biol       Date:  2011-04-22

Review 2.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

3.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

4.  Wharton's Jelly Transplantation Improves Neurologic Function in a Rat Model of Traumatic Brain Injury.

Authors:  Tian Cheng; Bo Yang; Dongpeng Li; Shanshan Ma; Yi Tian; Ruina Qu; Wenjin Zhang; Yanting Zhang; Kai Hu; Fangxia Guan; Jian Wang
Journal:  Cell Mol Neurobiol       Date:  2015-02-01       Impact factor: 5.046

Review 5.  Concise review: Can stem cells be used to treat or model Alzheimer's disease?

Authors:  Wesley W Chen; Mathew Blurton-Jones
Journal:  Stem Cells       Date:  2012-12       Impact factor: 6.277

6.  Defective neuromuscular transmission in the SOD1 G93A transgenic mouse improves after administration of human umbilical cord blood cells.

Authors:  Nizar Souayah; K M Coakley; R Chen; Norman Ende; Joseph J McArdle
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 7.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

8.  REVERSAL OF FIBRONECTIN-INDUCED HIPPOCAMPAL DEGENERATION WITH ENCAPSULATED MESENCHYMAL STROMAL CELLS.

Authors:  Jean-Pierre Dollé; Jeffrey Barminko; Sai Veruva; Casey Moure; Rene Schloss; Martin L Yarmush
Journal:  Nano Life       Date:  2013-12

Review 9.  Stem cell paracrine actions and tissue regeneration.

Authors:  Priya R Baraniak; Todd C McDevitt
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

10.  Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma.

Authors:  Thomas V Johnson; Natalie D Bull; David P Hunt; Nephtali Marina; Stanislav I Tomarev; Keith R Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.